Syndax Pharmaceuticals, Inc. (SNDX) earnings
SNDX earnings moved a median of +0.07% by the close. Quarterly and annual SNDX reports and results, each read against the price at its own news timestamp. Back to the SNDX overview →
30 measured SNDX earnings events.
Where these SNDX earnings landedvs 30 measured SNDX earnings reactions
| Middle 50% of SNDX earnings reactions | -1.39% to +3.03% |
|---|---|
| Median reaction (to close) | +0.07% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 SNDX earnings events with a measured close landed between -1.39% and +3.03%; 57% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Syndax Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +9.13% | +15.81% | |
| Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | +9.13% | +15.81% | |
| Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 | Press release | -1.17% | -4.15% | |
| Form 10-Q Syndax Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -2.26% | -9.86% | |
| Syndax Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | -2.26% | -9.86% | |
| Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 | Press release | -0.64% | +1.52% | |
| Form 10-K Syndax Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -0.05% | +9.76% | |
| Form 10-Q Syndax Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -0.52% | +12.87% | |
| Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | -0.52% | +12.87% | |
| Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025 | Press release | +2.31% | -2.09% | |
| Form 10-Q Syndax Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +0.24% | +1.29% | |
| Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +0.24% | +1.29% | |
| Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 | Press release | -0.36% | -0.93% | |
| Form 10-Q Syndax Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -3.50% | -18.15% | |
| Syndax Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -3.50% | -18.15% | |
| Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025 | Press release | +0.97% | +0.68% | |
| Form 10-K Syndax Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +1.15% | -3.55% | |
| Form 10-Q Syndax Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -2.52% | -1.39% | |
| Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -2.52% | -1.39% | |
| Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024 | Press release | +0.87% | +0.10% | |
| Form 10-Q Syndax Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +4.36% | +0.77% | |
| Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update | Press release | +4.36% | +0.77% | |
| Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 | Press release | -0.63% | +3.53% | |
| Form 10-Q Syndax Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -2.19% | +0.04% | |
| Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update | Press release | -2.19% | +0.04% | |
| Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 | Press release | +2.08% | +3.88% | |
| Form 10-K Syndax Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +2.61% | -0.95% | |
| Form 10-Q Syndax Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +1.88% | -0.80% | |
| Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update | Press release | +1.88% | -0.80% | |
| Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023 | Press release | +0.33% | +5.67% |
Keep exploring
More SNDX: analyst actions → · SEC filings → · SNDX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Adverum Biotechnologies, Inc. (ADVM) | 306 | 0.00% | 49% |
| Establishment Labs Holdings Inc. - Common Shares (ESTA) | 306 | +0.13% | 52% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 305 | +0.42% | 53% |
| U.S. Physical Therapy, Inc. (USPH) | 304 | -0.03% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.